Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO)

Vehreschild, J. J. ; Böhme, A. ; Cornely, O. A. ; Kahl, C. ; Karthaus, M. ; Kreuzer, K.-A ; Maschmeyer, G. ; Mousset, S. ; Ossendorf, V. ; Penack, O. ; Vehreschild, M. J. G. T. ; Bohlius, J.

In: Annals of Oncology, 2014, vol. 25, no. 9, p. 1709-1718

Ajouter à la liste personnelle
    We found convincing evidence from numerous randomised controlled trials that G-CSF, biosimilar G-CSF and pegfilgrastim reduce the risk to develop febrile neutropenia and infections. As a rule of thumb, it seems the relative benefit is highest for patients with an intermediate risk of infections. Compared to other guidelines, we rated the evidence for growth factors during AML induction chemotherapy and pegfilgrastim use in haematological malignancies lower